BullFrog AI Regains Nasdaq Compliance
Bullfrog AI Holdings shares are trading higher after the company announced that it secured funding into late 2027.
BullFrog AI Lands Major Pharma Deal And Secures Funding Into 2027
BullFrog AI Shares Surge On Deal With Top Pharma Company For MDD Drug Targets
BullFrog AI Lands Big Pharma Deal To Crack Depression Drug Targets
BullFrog AI Holdings shares are trading higher after the company announced a commercial agreement with a top five global pharmaceutical company to apply its proprietary bfLEAP platform to identify and prioritize novel drug targets in major depressive disorder.
BullFrog AI Strikes Commercial Agreement With Unnamed Pharma Firm To Deploy bfLEAP Platform
BullFrog AI Unveils Decision Engine To Tackle Drug Development Uncertainty
BullFrog AI Reveals bfARENAS Scenario-based Decision Engine, AI Intelligence Workflow Product To Define Drug Target Discovery And Clinical Trial Strategies
BullFrog to Host Webinar on New Precision AI Capability
RedChip Showcases Public Companies Across the Artificial Intelligence Value Chain at March 19 Virtual Investor Conference
Tuesday's session: gap up and gap down stocks
BullFrog AI to Unveil New Precision AI Capability
BullFrog AI To Unveil Scenario-Based Decision Engine For Pharmaceutical Portfolio Strategy And Clinical Trial Design; New Capabilities To Be Launched On March 25
BullFrog AI on Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences
BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer
BullFrog AI To Highlight bfLEAP Pancreatic Cancer Trial Data With ~3x Survival Gain At ASCO GI 2026
BullFrog AI Publishes Annual Letter to Shareholders
BullFrog AI and Myriad Uranium Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.